{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:04:08Z","timestamp":1791306248395,"version":"4.3.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2009,11,2]],"date-time":"2009-11-02T00:00:00Z","timestamp":1257120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2009,11,2]],"date-time":"2009-11-02T00:00:00Z","timestamp":1257120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1038\/bmt.2009.304","type":"journal-article","created":{"date-parts":[[2009,11,2]],"date-time":"2009-11-02T11:52:37Z","timestamp":1257162757000},"page":"1038-1046","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":119,"title":["Generation of donor natural killer cells from CD34+ progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study"],"prefix":"10.1038","volume":"45","author":[{"given":"S R","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y S","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S H","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K H","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je-H","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-H","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D Y","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y A","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Seol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S G","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J W","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K H","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,11,2]]},"reference":[{"key":"BFbmt2009304_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/jnci\/52.2.345","volume":"52","author":"EB Rosenberg","year":"1974","unstructured":"Rosenberg EB, McCoy JL, Green SS, Donnelly FC, Siwarski DF, Levine PH et al. Destruction of human lymphoid tissue-culture cell lines by human peripheral lymphocytes in 51Cr-release cellular cytotoxicity assays. J Natl Cancer Inst 1974; 52: 345\u2013352.","journal-title":"J Natl Cancer Inst"},{"key":"BFbmt2009304_CR2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/ijc.2910160205","volume":"16","author":"RB Herberman","year":"1975","unstructured":"Herberman RB, Nunn ME, Holden HT, Lavrin DH . Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer 1975; 16: 230\u2013239.","journal-title":"Int J Cancer"},{"key":"BFbmt2009304_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1146\/annurev.immunol.24.021605.090700","volume":"24","author":"JP Di Santo","year":"2006","unstructured":"Di Santo JP . Natural killer cell developmental pathways: a question of balance. Annu Rev Immunol 2006; 24: 257\u2013286.","journal-title":"Annu Rev Immunol"},{"key":"BFbmt2009304_CR4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1182\/blood-2007-09-077438","volume":"112","author":"MA Caligiuri","year":"2008","unstructured":"Caligiuri MA . Human natural killer cells. Blood 2008; 112: 461\u2013469.","journal-title":"Blood"},{"key":"BFbmt2009304_CR5","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1182\/blood-2002-02-0350","volume":"100","author":"SS Farag","year":"2002","unstructured":"Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA . Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002; 100: 1935\u20131947.","journal-title":"Blood"},{"key":"BFbmt2009304_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/sj.leu.2405040","volume":"22","author":"S Verheyden","year":"2008","unstructured":"Verheyden S, Demanet C . NK cell receptors and their ligands in leukemia. Leukemia 2008; 22: 249\u2013257.","journal-title":"Leukemia"},{"key":"BFbmt2009304_CR7","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1126\/science.285.5428.730","volume":"285","author":"J Wu","year":"1999","unstructured":"Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999; 285: 730\u2013732.","journal-title":"Science"},{"key":"BFbmt2009304_CR8","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","volume":"295","author":"L Ruggeri","year":"2002","unstructured":"Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097\u20132100.","journal-title":"Science"},{"key":"BFbmt2009304_CR9","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1182\/blood-2006-05-024315","volume":"109","author":"A Lundqvist","year":"2007","unstructured":"Lundqvist A, Philip McCoy J, Samsel L, Childs R . Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors. Blood 2007; 109: 3603\u20133606.","journal-title":"Blood"},{"key":"BFbmt2009304_CR10","first-page":"121","volume":"298","author":"S Gonzalez","year":"2006","unstructured":"Gonzalez S, Groh V, Spies T . Immunobiology of human NKG2D and its ligands. Curr Top Microbiol Immunol 2006; 298: 121\u2013138.","journal-title":"Curr Top Microbiol Immunol"},{"key":"BFbmt2009304_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nri999","volume":"3","author":"P Parham","year":"2003","unstructured":"Parham P, McQueen KL . Alloreactive killer cells: hindrance and help for haematopoietic transplants. Nat Rev Immunol 2003; 3: 108\u2013122.","journal-title":"Nat Rev Immunol"},{"key":"BFbmt2009304_CR12","first-page":"16","volume-title":"Thomas' Hematopoietic Cell Transplantation,","author":"PJ Martin","year":"2004","unstructured":"Martin PJ . Overview of hematopoietic cell transplantation immunology. In: Blume KG, Forman SJ, Appelbaum FR (eds). Thomas' Hematopoietic Cell Transplantation,, 3rd edn. Blackwell Publishing: Malden, MA, 2004, pp 16\u201330."},{"key":"BFbmt2009304_CR13","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1200\/JCO.2005.09.117","volume":"23","author":"F Aversa","year":"2005","unstructured":"Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447\u20133454.","journal-title":"J Clin Oncol"},{"key":"BFbmt2009304_CR14","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1182\/blood-2005-05-2146","volume":"107","author":"DP Lu","year":"2006","unstructured":"Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched\/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006; 107: 3065\u20133073.","journal-title":"Blood"},{"key":"BFbmt2009304_CR15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/sj.bmt.1705445","volume":"38","author":"XJ Huang","year":"2006","unstructured":"Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006; 38: 291\u2013297.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2009304_CR16","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1097\/01.TP.0000158718.49286.14","volume":"79","author":"Y Kanda","year":"2005","unstructured":"Kanda Y, Oshima K, Asano-Mori Y, Kandabashi K, Nakagawa M, Sakata-Yanagimoto M et al. In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation. Transplantation 2005; 79: 1351\u20131357.","journal-title":"Transplantation"},{"key":"BFbmt2009304_CR17","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.bbmt.2006.06.007","volume":"12","author":"H Ogawa","year":"2006","unstructured":"Ogawa H, Ikegame K, Yoshihara S, Kawakami M, Fujioka T, Masuda T et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biol Blood Marrow Transplant 2006; 12: 1073\u20131084.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2009304_CR18","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1200\/JCO.2006.07.0953","volume":"25","author":"DA Rizzieri","year":"2007","unstructured":"Rizzieri DA, Koh LP, Long GD, Gasparetto C, Sullivan KM, Horwitz M et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 2007; 25: 690\u2013697.","journal-title":"J Clin Oncol"},{"key":"BFbmt2009304_CR19","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641\u2013650.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2009304_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.bbmt.2008.10.025","volume":"15","author":"KH Lee","year":"2009","unstructured":"Lee KH, Lee JH, Kim DY, Kim SH, Shin HJ, Lee YS et al. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. Biol Blood Marrow Transplant 2009; 15: 61\u201372.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2009304_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/sj.bmt.1703779","volume":"31","author":"P Lewalle","year":"2003","unstructured":"Lewalle P, Triffet A, Delforge A, Crombez P, Selleslag D, De Muynck H et al. Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study. Bone Marrow Transplant 2003; 31: 39\u201344.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2009304_CR22","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3324\/haematol.10570","volume":"92","author":"XJ Huang","year":"2007","unstructured":"Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W . Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched\/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007; 92: 414\u2013417.","journal-title":"Haematologica"},{"key":"BFbmt2009304_CR23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nri2073","volume":"7","author":"HG Ljunggren","year":"2007","unstructured":"Ljunggren HG, Malmberg KJ . Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 2007; 7: 329\u2013339.","journal-title":"Nat Rev Immunol"},{"key":"BFbmt2009304_CR24","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1038\/sj.leu.2403524","volume":"18","author":"JR Passweg","year":"2004","unstructured":"Passweg JR, Tichelli A, Meyer-Monard S, Heim D, Stern M, Kuhne T et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004; 18: 1835\u20131838.","journal-title":"Leukemia"},{"key":"BFbmt2009304_CR25","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.exphem.2007.12.006","volume":"36","author":"A Schulze","year":"2008","unstructured":"Schulze A, Schirutschke H, Oelschlagel U, Schmitz M, Fussel M, Wassmuth R et al. Altered phenotype of natural killer cell subsets after haploidentical stem cell transplantation. Exp Hematol 2008; 36: 378\u2013389.","journal-title":"Exp Hematol"},{"key":"BFbmt2009304_CR26","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/j.1365-2141.2008.07340.x","volume":"143","author":"J Shi","year":"2008","unstructured":"Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol 2008; 143: 641\u2013653.","journal-title":"Br J Haematol"},{"key":"BFbmt2009304_CR27","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","volume":"105","author":"JS Miller","year":"2005","unstructured":"Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051\u20133057.","journal-title":"Blood"},{"key":"BFbmt2009304_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1016-8478(23)10750-3","volume":"24","author":"SR Yoon","year":"2007","unstructured":"Yoon SR, Chung JW, Choi I . Development of natural killer cells from hematopoietic stem cells. Mol Cells 2007; 24: 1\u20138.","journal-title":"Mol Cells"},{"key":"BFbmt2009304_CR29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2004.12.012","volume":"22","author":"KN Lee","year":"2005","unstructured":"Lee KN, Kang HS, Jeon JH, Kim EM, Yoon SR, Song H et al. VDUP1 is required for the development of natural killer cells. Immunity 2005; 22: 195\u2013208.","journal-title":"Immunity"},{"key":"BFbmt2009304_CR30","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/blood.V87.7.2632.bloodjournal8772632","volume":"87","author":"E Mrozek","year":"1996","unstructured":"Mrozek E, Anderson P, Caligiuri MA . Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood 1996; 87: 2632\u20132640.","journal-title":"Blood"},{"key":"BFbmt2009304_CR31","first-page":"635","volume-title":"Thomas' Hematopoietic Cell Transplantation","author":"K Sullivan","year":"2004","unstructured":"Sullivan K . Graft-vs host disease. In: Blume KG, Forman SJ, Appelbaum FR (eds). Thomas' Hematopoietic Cell Transplantation, 3rd edn. Blackwell Publishing: Malden, MA, 2004, pp 635\u2013664."},{"key":"BFbmt2009304_CR32","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945\u2013956.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2009304_CR33","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.bbmt.2006.04.008","volume":"12","author":"KC Hsu","year":"2006","unstructured":"Hsu KC, Gooley T, Malkki M, Pinto-Agnello C, Dupont B, Bignon JD et al. KIR Ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 2006; 12: 828\u2013836.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2009304_CR34","first-page":"931","volume":"90","author":"M Remberger","year":"2005","unstructured":"Remberger M, Sundberg B . Rabbit-immunoglobulin G levels in patients receiving thymoglobulin as part of conditioning before unrelated donor stem cell transplantation. Haematologica 2005; 90: 931\u2013938.","journal-title":"Haematologica"},{"key":"BFbmt2009304_CR35","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.autrev.2005.04.017","volume":"4","author":"A Poggi","year":"2005","unstructured":"Poggi A, Zocchi MR . Cyclosporin A regulates human NK cell apoptosis induced by soluble HLA-I or by target cells. Autoimmun Rev 2005; 4: 532\u2013536.","journal-title":"Autoimmun Rev"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2009304.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2009304","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2009304.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,17]],"date-time":"2024-03-17T11:56:14Z","timestamp":1710676574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2009304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,2]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["BFbmt2009304"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2009.304","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,2]]},"assertion":[{"value":"4 March 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2009","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2009","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2009","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KHL received an honorarium for a lecture from Genzyme. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}